Back to team overview
Dr. Eva Ehlich
Partner
German Patent Attorney
European Patent Attorney
UPC Representative
Chemist
Eva represents European, US and Japanese companies in the chemical, biochemical and pharmaceutical sectors whom she advises and assists in drafting, prosecuting, defending, enforcing and challenging IP rights in Germany, Europe and worldwide. Along with preparing freedom-to-operate and validity analyses she has experience in patent litigation and strategic patent filing, SPCs, especially in the area of drug delivery, pharmaceutics and medical uses (small molecules and biologics including vaccines) as well as in coordinating international patent portfolios and freedom-to-operate strategies. In this context she coordinates as hub-counsel team-lead large attorney teams including attorneys from Maiwald and international partner law firms.
Eva has received numerous recognitions for her professional activities as a patent attorney.
Eva Ehlich does superb work building comprehensive patent portfolios, as well as supporting on litigation projects, which often includes coordinating local counsel. She is impressive in her ability to deal with challenging cases, overcoming any obstacle and hurdle placed in her way. Eva is particularly appreciated for her attention to detail, strategic thinking and ability to achieve excellent results.
– IAM Patent 1000, 2025
- Patent prosecution and portfolio management
- Filing strategies and drafting patent applications
- Freedom-to-operate and validity opinions
- Opposition and nullity proceedings
- Patent litigation
- Recommended in IAM Patent 1000 “World’s Leading Patent Professionals” 2020, 2021, 2022, 2023, 2025
- Listed in IAM Strategy 300 Global Leaders 2022, 2023, 2024, 2025
- Listed in Who's Who Legal, recommended in the "Germany" and "IP" Ranking 2024
- Recommended by IAM Strategy 300 as the World's leading IP Strategist 2021, 2022, 2023, 2024
- Listed as "Excellent" in the Leaders League Rankings Germany 2022 and 2023 in the categorie Patent Prosecution, listed as "Leading" in 2024
- Recommended in MIP IP Stars 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Recommended in Legal 500 EMEA 2019, 2020, 2021, 2022, 2023, 2024
- Recommended in Legal 500 Deutschland 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Recommended in Handelsblatt | Best Lawyers "Germany's Best Lawyers" 2019, 2020, 2021, 2022, 2023
- "Recommended individuals" in JUVE Patent Rankings Germany 2021, 2022, 2023, 2024
- Featured among Managing IP’s Top 250 Women in IP 2022
- "Frequently recommended lawyer" in the JUVE Handbook of Commercial Law Firms 2017/ 2018, 2017/2018, 2018/2019, 2019/2020, 2020/2021, 2021/2022
- Interview IAM Strategy 300 Global Leaders, 2024
- Patenting medical treatments in the US and Europe – a guide for practitioners, Managing IP 2024
- Podcast – Empowering women and nurturing young talent: Maiwald’s commitment to equality and diversity, MIP, 2024
- Is the medical use disclosure standard different for novelty and sufficiency?, Managing IP, 2024
- Promoting women and young talent at MAIWALD, 2024
- Reliance on a purported technical effect for inventive step – Quo vadis “plausibility” after G 2/21? epi Information, 1/2024
- Products eligible for the medical use format under the EPC: new insights, Managing IP 2024
- T 0116/18 and a review after 10 months of G 2/21, Managing IP 2024
- Co-chair at the 3rd Annual Life Science Strategy Summit on IP & Exclusivity in Munich, 2024 – Lecture title: “Transcontinental Update on Regulatory and IP Strategies Surrounding Clinical Trials”
- Maiwald makes the case for patent lawyers to learn something new: LiquidText, The Patent Lawyer (Annual 2024)
- Interview IAM Strategy 300 Global Leaders, 2023
- JUVE Handbook 2021/2022: Co-publishing article on the topic of „Chancen und Stolpersteine bei Videoverhandlungen am EPA“
- What is Horizon Europe about? (2021)
- Germany: EBA Set to Hear Case on the Legality of the EPO’s Video Proceedings, 2021
- Patente treiben Innovation und Fortschritt, 2021
- R 0016/13 – A truly positive decision! (2015)
- Opposition against EP 3 679 915 concerning a dengue vaccine (Opposition Division)
- Appeal T2303/19 concerning a vaccine composition (Board of Appeal)
- Appeal T1977/21 concerning attenuated viruses (Board of Appeal)
- Appeal T0489/20 concerning a transdermal system for treating pain (Board of Appeal)
- 2 BvR 561/18, 2 BvR 756/16, 2 BvR 786/15 regarding the independence of the Boards of Appeal (German Constitutional Court)
- R 02/15, R 05/15, R 08/13 regarding the independence of members of the Boards of Appeal and the right to be heard (Enlarged Board of Appeal)
- T1938/09 regarding a transdermal system for treating pain (Board of Appeal)
- 315 O 383/17 regarding a transdermal system for treating pain (District Court of Hamburg)
- 21 O 6972/16, 4c O 20/16 regarding a transdermal system for treating pain (district court of Munich)
- T0259/15 regarding a transdermal system for treating pain (Board of Appeal)
- T1676/08 regarding an oral controlled release pain medicament (Board of Appeal)
- German Patent Attorney Association
- AIPPI
- epi
- FICPI
- GRUR
- German
- English
